Press Release – New York, NY – February 11, 2026 – Sichenzia Ross Ference Carmel LLP announced today that it represented Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, in its recently priced private placement offering of Series A Convertible Preferred Stock, for up to $21 million (including an initial closing of $11 million).
The SRFC team was led by partner Arthur Marcus, with counsel Michael Nacht and associate Jesse Blue.